Latest Industry Insights

The intricate and intertwined nature of the host‒microbiota connection has garnered increasing interest from the scientific community in recent years, due to its known role in the development and progression of various diseases. 4D pharma has leveraged growing knowledge in the field, by creating a novel class of medicines called live biotherapeutic products (LBPs).

In this interview we speak to Sean Mackay, CEO of IsoPlexis, to discuss how single-cell functional proteomics have helped researchers understand the risk factors behind long COVID.

Emulate's chief scientific officer, Dr. Lorna Ewart, talks about inspiring a new generation of women in STEM.

Technology Networks spoke to Dr. Tomas Richardson from PBD Biotech, to hear more about how bacteriophage can be used to diagnose tuberculosis in both humans and cattle.

Technology Networks spoke to Atara’s chief medical officer, AJ Joshi, to learn more about ATA188 – an off-the-shelf, allogeneic T-cell immunotherapy – and how it could revolutionize treatment for MS patients.

Technology Networks recently spoke with Jakob Dupont, head of global research & development at Atara Bio, to learn more about the company’s novel allogeneic EBV T-cell platform and discover how it’s enabling a differentiated approach to allogeneic cell therapy.

In honor of International Day of Women and Girls in Science 2022, Technology Networks interviewed three women who have built successful careers within the scientific industry, to learn about their career paths and the reasons they chose to work in industry.

In this interview, we speak to Dr. Antal Szalay, CEO of Ultimate Medicine, about how his company helped establish that a microbiome metabolite can cause age-related memory loss.

Therapies are needed for patients with autoimmune disorders such as lupus. Technology Networks spoke to Cherie Ng, the senior director for research at Equillium, about how the first-in-class anti-CD6 therapy was designed.

Technology Networks spoke with Michael Yang, president and chief executive officer of ViaCyte, to learn more about the development of a stem cell-derived therapy for the treatment of T1D and the technology behind it.